Study of CREPT-618 for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This phase 1 trial tests a new drug called CREPT-618 for people with advanced liver cancer that hasn't responded to standard treatments. The drug is designed to target cancer cells with specific markers (CREPT and ASGPR), so only patients whose tumors have these markers can join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced liver cancer (hepatocellular carcinoma or HCC) that cannot be removed with surgery or has spread, and standard treatments have stopped working.
- Your liver tumor tissue must have high levels of two markers called CREPT and ASGPR. (Your doctor checks this from a biopsy or old tissue sample.)
- You do not have active hepatitis B or C, and your liver is working fairly well (specific blood test results required).
- You have not had certain cancer treatments (like chemotherapy or immunotherapy) in the past few weeks, and you have no major health problems like severe liver failure or other cancers.
- You agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
This trial tests a new drug called TPST-1120 combined with two standard treatments (atezolizumab and bevacizumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination works better than the standard approach alone.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.